Skip to main content

bioMérieux S.A. (BMXXY)

OTC Markets (US) Healthcare Medical - SpecialtiesView data quality →
55.6Fair

ValueMarkers Composite Index

Top 59%#18,133 of 44,707
Slightly Undervalued

0% below intrinsic value ($15)

UndervaluedFair ValueOvervalued
Piotroski
6/9
Neutral
Beneish
-2.72
Low Risk
Altman
7.33
Safe
DCF Value
$15
Overvalued
ROIC
6.3%
Low
P/E
26.7
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

bioMérieux S.A. (BMXXY) — VMCI valuation read

BMXXY prints VMCI 56/100 inside the Healthcare sector, where the median sits at 50. The 6-point above-median delta is the cleanest single-number summary of bioMérieux S.A.'s composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.

On BMXXY, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** BMXXY trades at 22.0x earnings, 22% above the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of -0.6x leaves covenant headroom; that is the risk line for bioMérieux S.A. on the trailing financials.

BMXXY fell 2.7% over the trailing 7 days, with a -18.9% read on a 30-day basis.

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

CEO: Pierre Boulud14,147 employeesFRwww.biomerieux.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in BMXXY’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.